Doximity (NYSE: DOCS) shares surge 55% as clinical AI adoption transforms the earnings story despite weaker profit

Doximity, Inc. (NYSE: DOCS) shares surged approximately 55% to around $32 in early New York trading on August 7, 2026, after the digital healthcare platform reported fiscal first-quarter revenue of $156.6 million and disclosed accelerating physician use of its artificial intelligence products. Revenue increased 7% year on year and exceeded the company’s previous guidance of $151 million to $152 million, while workflow active prescribers grew by more than 30% and AI Search queries increased more than 25% sequentially. The enthusiasm came despite adjusted EBITDA declining 6% to $74.8 million, non-GAAP diluted earnings falling to $0.29 from $0.36 and free cash flow dropping 34% to $39.6 million. The unusual combination of weakening near-term profitability and an explosive share-price rally suggests the market is reassessing Doximity around the commercial potential of its clinical AI ecosystem rather than simply rewarding the latest quarter’s earnings.

That distinction makes Doximity one of the more interesting healthcare technology earnings stories of the current reporting season. Only three months earlier, the company’s shares had fallen sharply after management issued fiscal 2027 revenue guidance below Wall Street expectations, raising concerns that its historically high-margin pharmaceutical marketing business was entering a slower growth phase. The latest quarter does not completely remove those concerns, but it offers evidence that physician engagement with Doximity Ask, Scribe and other workflow products could create a new growth engine at a time when artificial intelligence is reshaping how clinicians search medical literature, document consultations and manage administrative work.

The central tension is therefore unusually clear. Doximity is investing more aggressively in research, sales and artificial intelligence infrastructure, which is compressing margins and reducing current cash generation, yet those investments may also be expanding the company’s addressable market beyond its traditional advertising and professional-networking model. Investors now have to determine whether the August rally represents a rational rerating toward a healthcare AI platform with unusual physician distribution, or whether enthusiasm has moved substantially faster than the financial evidence.

Why did Doximity shares surge when adjusted EBITDA and earnings actually declined year on year?

The first-quarter income statement would not normally explain a share-price move of this magnitude. Revenue rose 7% to $156.6 million, but adjusted EBITDA declined from $79.8 million to $74.8 million and the adjusted EBITDA margin contracted from 54.7% to 47.7%. GAAP net income fell to $24.3 million from $53.3 million, while non-GAAP net income declined to $55 million from $71.9 million. Operating cash flow dropped 32% to $42 million, and free cash flow fell from $60.1 million to $39.6 million.

The market instead appears to have focused on the direction of revenue growth and product engagement. Doximity had guided for only $151 million to $152 million of first-quarter revenue in May, so the reported $156.6 million demonstrated that demand had accelerated beyond management’s conservative assumptions. The company also increased full-year revenue guidance to between $671 million and $681 million from the previous range of $664 million to $676 million, while forecasting second-quarter revenue of $170 million to $171 million.

There is an important complication. Doximity simultaneously reduced its full-year adjusted EBITDA range to $309 million to $329 million from the $323 million to $335 million forecast provided in May, which means management is effectively signalling that some incremental revenue opportunity will be accompanied by heavier investment. Investors nevertheless rewarded the stock because higher spending on artificial intelligence may be viewed differently from margin deterioration caused by weak pricing or customer losses. If the spending builds products capable of deepening physician engagement and creating new enterprise revenue streams, temporarily lower margins could represent growth investment rather than declining business quality.

The August 7 reaction therefore resembles a narrative reset more than a conventional earnings beat. Doximity entered the quarter with subdued growth expectations and significant concern that artificial intelligence could disrupt parts of its existing business; it emerged with evidence that AI may instead strengthen the company’s competitive position, at least if current usage trends eventually translate into durable commercial revenue.

How important are Doximity Ask and Scribe to the company’s emerging healthcare AI strategy?

Doximity’s strongest competitive asset is not simply its software. The company says its professional network includes more than 85% of physicians in the United States, giving it a distribution channel that most healthcare AI startups would need years and substantial capital to replicate. That installed user base potentially allows Doximity to introduce new clinical tools directly into workflows already used by physicians for communication, medical research, scheduling, documentation and professional information.

Doximity Ask is becoming the centrepiece of that strategy. The HIPAA-compliant clinical AI assistant provides evidence-backed responses to medical questions and uses the company’s PeerCheck programme, through which physician reviewers evaluate AI-generated material for clinical accuracy, completeness and source quality. Doximity said in July that more than 11,000 physician contributors had participated in the programme, while the Clinical AI Suite had been reviewed, approved and deployed across more than 150 health systems, including eight of the 20 largest hospitals in the United States.

The company also has Scribe, an ambient documentation product designed to generate clinical notes while physicians interact with patients. This places Doximity in one of the most competitive areas of healthcare AI, as hospitals and doctors seek tools that can reduce the administrative burden associated with electronic health records and clinical documentation.

Usage data is becoming increasingly important because it provides a bridge between product announcements and commercial adoption. Doximity reported that workflow active prescribers increased by more than 30% year on year during the first quarter, while AI Search queries rose more than 25% from the previous quarter. At the end of fiscal 2026, more than 800,000 active prescribers were already using Doximity workflow tools, and nearly half had used the company’s clinical AI during the fourth quarter.

If those users continue moving from occasional experimentation toward routine clinical use, Doximity could create a substantially more defensible engagement layer around its physician network.

Does Doximity’s clinical AI safety performance give it a meaningful advantage over general AI models?

Clinical artificial intelligence operates under a fundamentally different risk profile from consumer AI because inaccurate, incomplete or poorly contextualised information can affect medical decision-making. Doximity has therefore placed considerable emphasis on clinical grounding, physician review and the ability to trace answers to medical literature rather than competing solely on the general reasoning capabilities of large language models.

That strategy received additional visibility in July when Doximity Ask performed strongly in the NOHARM benchmark developed by the ARISE clinical AI research group, which is led by physicians associated with Stanford University School of Medicine and Harvard Medical School. The evaluation used more than 1,100 physician-derived clinical scenarios spanning 10 medical specialties and assessed whether recommendations could contribute to patient harm. Doximity reported that Ask ranked first among the systems evaluated on the real-world clinical sample.

The result should be interpreted carefully rather than treated as proof of universal clinical superiority. Independent benchmarking remains an evolving field, model performance can change quickly as systems are updated, and competing companies have questioned aspects of the methodology. The broader finding is nevertheless strategically important because purpose-built clinical AI systems performed strongly relative to several general-purpose models, supporting the argument that medical workflows may reward specialised systems that combine retrieval, clinical data, human oversight and domain-specific interfaces.

For Doximity, this creates a potentially attractive competitive position. It does not need to build the world’s most powerful general-purpose foundation model if it can combine available AI technology with physician distribution, healthcare-specific data architecture, medical references, enterprise security and clinical review in a way hospitals are willing to deploy.

The commercial question is whether that differentiation becomes pricing power.

Can Doximity convert physician AI engagement into a larger enterprise healthcare business?

Doximity historically generated much of its economic value by connecting pharmaceutical companies and other healthcare customers with a highly verified physician audience. That business has produced unusually high software-style margins because the platform can monetise professional engagement without the heavy physical infrastructure required by conventional healthcare providers.

Clinical AI opens a different route to expansion. Rather than monetising physicians principally as an audience for customers, Doximity can increasingly sell workflow technology that physicians themselves use inside clinical practice, while also offering health systems and physician organisations enterprise-level deployment.

The May partnership with Aledade illustrates that direction. Doximity is integrating Scribe and Ask into Aledade Assist, the electronic health record overlay used across Aledade’s value-based care network. The arrangement gives Doximity a route into independent medical practices while embedding its AI products more deeply into actual patient-care workflows rather than requiring clinicians to visit a standalone application.

This embedded-distribution strategy could become one of Doximity’s most important advantages. Healthcare organisations are already confronting an expanding number of AI vendors, which creates concerns around cybersecurity, regulatory compliance, workflow fragmentation and technology procurement. A platform that can bundle clinical search, documentation and communication inside an environment physicians already recognise may reduce deployment friction.

However, adoption alone does not guarantee attractive economics. Hospitals are demanding increasingly sophisticated AI capabilities while scrutinising technology budgets, and competing products are proliferating rapidly. Doximity must demonstrate that customers will pay enough for its clinical AI products to justify the increased research, development and sales expenditure required to build and support them.

Why are Doximity’s margins and free cash flow falling as management increases artificial intelligence spending?

The clearest evidence of the investment cycle can be seen in operating expenses. Research and development expenditure increased to $38.5 million during the first quarter from $26.8 million a year earlier, while sales and marketing expenses rose to $45 million from $36.4 million. Total operating expenses consequently increased 31% to $99.3 million, considerably faster than the 7% increase in revenue.

Stock-based compensation also increased sharply, rising to $36.8 million from $21.9 million. Research and development accounted for $15.6 million of the current quarter’s stock-based compensation compared with just $6.6 million one year earlier, suggesting that technical hiring and retention are contributing materially to the cost increase.

This spending explains why GAAP operating income declined to $33.6 million from $54.5 million even though gross profit increased modestly. It also creates an important distinction between Doximity’s underlying business economics and the adjusted numbers highlighted by management, since stock-based compensation is excluded from adjusted EBITDA but remains economically relevant to shareholders through potential dilution and compensation cost.

Doximity has offset part of that dilution through aggressive share repurchases. The company spent approximately $91.6 million repurchasing stock during the quarter, following $122.4 million in the comparable prior-year period. Its balance sheet remains strong, with approximately $273.6 million of cash and $414.2 million of marketable securities at the end of June, giving management substantial flexibility to continue investment without relying on external financing.

The financial question is therefore not whether Doximity can afford its AI strategy. It can. The more important issue is whether the incremental spending generates enough new revenue and strategic value to restore operating leverage over the next several years.

Does the 55% Doximity share-price surge represent a sustainable AI rerating or an expectations rebound?

The scale of the rally needs to be understood in the context of what happened before it. Doximity shares had fallen heavily after the May results because management’s initial fiscal 2027 guidance implied much slower growth than investors had become accustomed to, while concerns about competitive disruption and AI investment added to pressure on the valuation. Barron’s reported at the time that the shares dropped sharply after Doximity forecast fiscal 2027 revenue below Wall Street expectations.

That prior pessimism created the conditions for an unusually violent reassessment when the first-quarter revenue trajectory came in better than feared. Early Friday trading lifted Doximity roughly 55% to around $32, after even larger gains had appeared during after-hours and premarket trading.

The market is effectively assigning greater value to three things: stronger-than-guided revenue, accelerating clinical AI engagement and evidence that Doximity’s physician network could become a distribution advantage in healthcare AI. None of those factors changes the fact that adjusted EBITDA, earnings and cash flow declined during the quarter, which means the rerating is being driven largely by expectations of future monetisation rather than a present improvement in profit.

That makes subsequent quarters unusually important. A stock can sustain a higher multiple if revenue growth continues accelerating while AI products generate credible commercial traction, but the valuation becomes vulnerable if user engagement grows without corresponding revenue or if margins continue declining more quickly than management can justify through future opportunity.

The August move may therefore mark the beginning of a genuine strategic rerating, but the evidence required to sustain it will be considerably more demanding than the evidence required to trigger it.

What are the key takeaways from Doximity’s Q1 FY27 results and clinical AI-driven stock rally?

• Doximity reported fiscal Q1 2027 revenue of $156.6 million, up 7% year on year and above its previous guidance range.
• Doximity shares surged roughly 55% to around $32 during early trading on August 7 after much larger premarket volatility.
• Workflow active prescribers increased by more than 30% year on year, while AI Search queries grew more than 25% sequentially.
• Adjusted EBITDA declined 6% to $74.8 million as the adjusted EBITDA margin fell to 47.7%.
• Free cash flow declined 34% to $39.6 million as operating expenses and AI-related investment increased.
• Doximity raised fiscal 2027 revenue guidance to $671 million to $681 million but lowered its adjusted EBITDA range.
• Doximity Ask has been deployed as part of the company’s Clinical AI Suite across more than 150 health systems.
• The Aledade partnership provides another route for embedding Doximity Ask and Scribe directly into physician workflows.
• The company retains substantial liquidity, supporting continued investment despite weaker near-term cash generation.
• The next phase of the investment case depends on whether rapidly growing AI engagement translates into enterprise revenue and renewed operating leverage.

What must Doximity prove next for its clinical AI rally to become a durable growth story?

Doximity has accomplished something significant with its first-quarter update: it has shifted the investor debate away from whether artificial intelligence threatens the existing business and toward whether artificial intelligence could materially expand it. That change helps explain why the shares reacted so strongly despite financial results that, viewed in isolation, showed declining earnings, weaker cash generation and substantial margin compression.

The company has several assets that give the strategy credibility, including access to a large proportion of United States physicians, an established healthcare advertising and workflow business, substantial liquidity, enterprise relationships and a clinical AI platform that is already being deployed across major health systems. Those advantages could allow Doximity to become an important distribution and workflow layer between doctors, medical information and artificial intelligence.

What remains unresolved is monetisation. Physician adoption can validate product usefulness, but investors ultimately need evidence that AI Search, Doximity Ask, Scribe and related enterprise deployments can generate incremental revenue that grows faster than the additional research, infrastructure and sales expenditure required to support them.

The next two quarters should provide that evidence more clearly. Second-quarter revenue of $170 million to $171 million would imply another step up from Q1, while continued sequential acceleration in AI usage would strengthen the argument that adoption has not peaked after an initial period of experimentation. At the same time, adjusted EBITDA and free cash flow will show how much profitability Doximity is prepared to sacrifice while it pursues the opportunity.

The August 7 rally therefore does not demonstrate that Doximity has already won the clinical AI market. It demonstrates that investors are suddenly willing to pay much more for the possibility that its physician network can become a distribution advantage in that market. The decisive test will be whether that possibility begins appearing in revenue and operating leverage before expectations once again outrun the numbers.